With a deep­er dis­count in place, NICE now ready to en­dorse use of No­var­tis' Kym­ri­ah in adult lym­phoma pa­tients

Looks like No­var­tis has made nice with UK’s NICE. The cost-ef­fec­tive­ness watch­dog re­versed its Sep­tem­ber po­si­tion to en­dorse the Swiss drug­mak­er’s CAR-T ther­a­py, Kym­ri­ah, in adult lym­phoma pa­tients, af­ter ac­cept­ing a deep­er dis­count on a ther­a­py that car­ries a list price of £282,000 (rough­ly $368232), it said on Fri­day.

Kym­ri­ah was the first CAR-T drug to win ap­proval in the Unit­ed States and Eu­rope, but sales have suf­fered due to man­u­fac­tur­ing wob­bles. Still, the com­pa­ny ex­pects the drug — which reengi­neers a pa­tient’s’ im­mune cells to rec­og­nize and at­tack can­cer — to even­tu­al­ly gen­er­ate block­buster sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER